Clinical Trial Update: A Global Study to Assess the Effects of MEDI4736 (Durvalumab) in Patients With Locally Advanced or Metastatic Non Small Cell Lung Cancer [Phase 2]

View source ↗

Summary

A Phase 2 global trial evaluating durvalumab (MEDI4736) in locally advanced or metastatic non-small cell lung cancer has completed, with results posted in Janua…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• Durvalumab (durvalumab)

Snippet

Sponsor: AstraZeneca | Conditions: Non-Small Cell Lung Cancer | Phase 2 | Status: COMPLETED | Results posted: 2018-01-03